San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Spinogenix is raising $2,262,403.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Stella Sarraf played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Spinogenix

Our mission is to create transformative therapeutics for diseases involving synaptic loss and dysfunction. Our approach is focused on regenerating synapses to reverse declines in cognitive and motor function. This approach is unique among the many therapeutics that are being developed for neurodegenerative conditions, which mostly aim to slow the degenerative process. We envision the use of SPGs as a monotherapy or in combination with other therapeutics that target disease-specific degenerative processes.

To learn more about Spinogenix, visit http://www.spinogenix.com/

Contact:
Stella Sarraf, President and Chief Executive Officer
310-926-9930
stella@spinogenix.com
https://www.linkedin.com/in/stellasarraf/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved